540 related articles for article (PubMed ID: 16736505)
1. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.
Hua J; Kirou K; Lee C; Crow MK
Arthritis Rheum; 2006 Jun; 54(6):1906-16. PubMed ID: 16736505
[TBL] [Abstract][Full Text] [Related]
2. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.
Kirou KA; Lee C; George S; Louca K; Papagiannis IG; Peterson MG; Ly N; Woodward RN; Fry KE; Lau AY; Prentice JG; Wohlgemuth JG; Crow MK
Arthritis Rheum; 2004 Dec; 50(12):3958-67. PubMed ID: 15593221
[TBL] [Abstract][Full Text] [Related]
3. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells.
Karonitsch T; Feierl E; Steiner CW; Dalwigk K; Korb A; Binder N; Rapp A; Steiner G; Scheinecker C; Smolen J; Aringer M
Arthritis Rheum; 2009 May; 60(5):1463-71. PubMed ID: 19404947
[TBL] [Abstract][Full Text] [Related]
4. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
[TBL] [Abstract][Full Text] [Related]
5. IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Rodríguez-Carrio J; López P; Alperi-López M; Caminal-Montero L; Ballina-García FJ; Suárez A
Front Immunol; 2018; 9():3085. PubMed ID: 30666255
[No Abstract] [Full Text] [Related]
6. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Wang H; Li T; Chen S; Gu Y; Ye S
Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
[TBL] [Abstract][Full Text] [Related]
7. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
[TBL] [Abstract][Full Text] [Related]
8. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.
Niewold TB; Kelly JA; Flesch MH; Espinoza LR; Harley JB; Crow MK
Arthritis Rheum; 2008 Aug; 58(8):2481-7. PubMed ID: 18668568
[TBL] [Abstract][Full Text] [Related]
9. Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.
Morimoto AM; Flesher DT; Yang J; Wolslegel K; Wang X; Brady A; Abbas AR; Quarmby V; Wakshull E; Richardson B; Townsend MJ; Behrens TW
Arthritis Rheum; 2011 Aug; 63(8):2407-15. PubMed ID: 21506093
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.
Enocsson H; Wetterö J; Eloranta ML; Gullstrand B; Svanberg C; Larsson M; Bengtsson AA; Rönnblom L; Sjöwall C
Front Immunol; 2021; 12():688753. PubMed ID: 34276678
[TBL] [Abstract][Full Text] [Related]
11. Anti-interferon alpha treatment in SLE.
Kirou KA; Gkrouzman E
Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
[TBL] [Abstract][Full Text] [Related]
12. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
[TBL] [Abstract][Full Text] [Related]
13. Interferon-lambda1 induces peripheral blood mononuclear cell-derived chemokines secretion in patients with systemic lupus erythematosus: its correlation with disease activity.
Wu Q; Yang Q; Lourenco E; Sun H; Zhang Y
Arthritis Res Ther; 2011 Jun; 13(3):R88. PubMed ID: 21679442
[TBL] [Abstract][Full Text] [Related]
14. PTPN22 Variant R620W Is Associated With Reduced Toll-like Receptor 7-Induced Type I Interferon in Systemic Lupus Erythematosus.
Wang Y; Ewart D; Crabtree JN; Yamamoto A; Baechler EC; Fazeli P; Peterson EJ
Arthritis Rheumatol; 2015 Sep; 67(9):2403-14. PubMed ID: 26018863
[TBL] [Abstract][Full Text] [Related]
15. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.
Slight-Webb S; Lu R; Ritterhouse LL; Munroe ME; Maecker HT; Fathman CG; Utz PJ; Merrill JT; Guthridge JM; James JA
Arthritis Rheumatol; 2016 Oct; 68(10):2492-502. PubMed ID: 27059145
[TBL] [Abstract][Full Text] [Related]
16. Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases.
Gupta S; Tatouli IP; Rosen LB; Hasni S; Alevizos I; Manna ZG; Rivera J; Jiang C; Siegel RM; Holland SM; Moutsopoulos HM; Browne SK
Arthritis Rheumatol; 2016 Jul; 68(7):1677-87. PubMed ID: 26815287
[TBL] [Abstract][Full Text] [Related]
17. Interactions among type I and type II interferon, tumor necrosis factor, and beta-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus.
Lee HM; Mima T; Sugino H; Aoki C; Adachi Y; Yoshio-Hoshino N; Matsubara K; Nishimoto N
Arthritis Res Ther; 2009; 11(1):R1. PubMed ID: 19121222
[TBL] [Abstract][Full Text] [Related]
18. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.
Niewold TB; Kelly JA; Kariuki SN; Franek BS; Kumar AA; Kaufman KM; Thomas K; Walker D; Kamp S; Frost JM; Wong AK; Merrill JT; Alarcón-Riquelme ME; Tikly M; Ramsey-Goldman R; Reveille JD; Petri MA; Edberg JC; Kimberly RP; Alarcón GS; Kamen DL; Gilkeson GS; Vyse TJ; James JA; Gaffney PM; Moser KL; Crow MK; Harley JB
Ann Rheum Dis; 2012 Mar; 71(3):463-8. PubMed ID: 22088620
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
[TBL] [Abstract][Full Text] [Related]
20. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.
Munroe ME; Lu R; Zhao YD; Fife DA; Robertson JM; Guthridge JM; Niewold TB; Tsokos GC; Keith MP; Harley JB; James JA
Ann Rheum Dis; 2016 Nov; 75(11):2014-2021. PubMed ID: 27088255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
